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Abstract
This paper summarises key advances in defining the infectious reservoir for malaria and the
measurement of transmission for research and programmatic use since the Malaria Eradi-
cation Research Agenda (malERA) publication in 2011. Rapid and effective progress
towards elimination requires an improved understanding of the sources of transmission as
well as those at risk of infection. Characterising the transmission reservoir in different set-
tings will enable the most appropriate choice, delivery, and evaluation of interventions.
Since 2011, progress has been made in a number of areas. The extent of submicroscopic
and asymptomatic infections is better understood, as are the biological parameters govern-
ing transmission of sexual stage parasites. Limitations of existing transmission measures
have been documented, and proof-of-concept has been established for new innovative
serological and molecular methods to better characterise transmission. Finally, there now
exists a concerted effort towards the use of ensemble datasets across the spectrum of met-
rics, from passive and active sources, to develop more accurate risk maps of transmission.
These can be used to better target interventions and effectively monitor progress toward
elimination. The success of interventions depends not only on the level of endemicity but
also on how rapidly or recently an area has undergone changes in transmission. Improved
understanding of the biology of mosquito–human and human–mosquito transmission is
needed particularly in low-endemic settings, where heterogeneity of infection is pronounced
and local vector ecology is variable. New and improved measures of transmission need to
be operationally feasible for the malaria programmes. Outputs from these research priorities
should allow the development of a set of approaches (applicable to both research and con-
trol programmes) that address the unique challenges of measuring and monitoring transmis-
sion in near-elimination settings and defining the absence of transmission.
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Summary points
• Understanding the sources of transmission (the infectious reservoir) and those at risk of
infection at the population level in order to inform programmatic decision-making can
progress malaria elimination.
• There is considerable evidence for malaria infections at densities beneath the limit of
conventional diagnostics. However, the contribution of these low-density infections to
malaria transmission in different settings is not known.
• Characterising the spatial and temporal heterogeneity of the infectious reservoir becomes
increasingly important as transmission declines if interventions are to be efficiently
implemented to accelerate malaria elimination.
• The proportional contributions of low-density, asymptomatic, and symptomatic infec-
tions will differ by malaria typology and will determine the programmatic approach
required to reduce transmission.
• Plasmodium vivax hypnozoites are undetectable with currently available diagnostics,
representing a major barrier to both understanding the transmission reservoir for this
parasite and its elimination.
• There is a need to standardise both existing transmission metrics and new metrics with
greater sensitivity, particularly for their use in low-transmission settings.
Introduction
Transmission of malaria requires sexual-stage parasites, gametocytes, in humans to be taken
up by female Anopheles mosquitoes when they feed. After a period of parasite development,
mosquitoes can then infect humans. A break in this cycle at any point interrupts malaria trans-
mission. Malaria control has historically focussed on the reduction of morbidity and mortality
of the human host rather than on the interruption of transmission from human to mosquito.
Understanding the variation in the relationship between infection (the presence of parasites in
an individual or mosquito) and infectiousness (the ability to transmit parasites to a mosquito
or human) at different transmission intensities and with different levels of intervention cover-
age is increasingly recognised as critical in the pursuit of malaria elimination.
In 2011, one of the main conclusions of the Malaria Eradication Research Agenda (mal-
ERA) process was the need to develop tools to measure transmission at low levels in elimina-
tion contexts. This article summarizes progress made since 2011 and for the first time develops
a research agenda addressing the reservoir of transmissible parasites and measuring transmis-
sion [1,2]. Findings and recommendations presented here result from a systematic search of
the literature and the deliberations of the 2015 malERA Refresh Consultative Panel on charac-
terising the reservoir and measuring transmission, including specialists from field and imple-
mentation science, entomology, epidemiology, and basic science.
Since the 2011 malERA process, research has ranged from illuminating the basic biology of
the development of sexual-stage parasites in humans and mosquitoes to evaluating operational
approaches targeting infectious individuals in endemic communities. Additionally, a harmo-
nised set of definitions relevant to malaria transmission and elimination has been developed
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(Box 1) [3]. However, there remains a need to further validate a ‘toolkit’ of metrics and associ-
ated surveillance activities to characterise the infectious reservoir and measure malaria trans-
mission that can be applied programmatically to direct and evaluate interventions and to
quantify progress towards malaria elimination. There are multiple factors that contribute to
malaria epidemiology including ecology, vectors, parasites, human biology and behaviour, and
economic and health-system factors (see Box 1), and these collectively make up a given ‘typol-
ogy’ of malaria. The selection of appropriate surveillance activities and metrics from this
toolkit will not only need to reflect variations in malaria ‘typology’ (Box 1) [3], but will need to
be adapted as malaria transmission declines (Fig 1).
This paper discusses progress in the measurement and understanding of malaria transmis-
sion, highlighting the different malaria typologies in which transmission occurs (Box 1). This
differentiation between typologies is needed to determine where existing strategies and sys-
tems can sufficiently achieve malaria elimination versus those where additional approaches or
tools are required.
Research agenda for characterising the reservoir of infection
Detecting malaria: Infection versus transmission
Malaria infection and transmission can be detected and measured with a variety of metrics
(Tables 1 and 2). Their suitability and discriminatory power, however, can vary widely across
settings and populations. To reliably confirm clinical malaria, a minimum diagnostic sensitiv-
ity of 200 parasites/μL blood is required [6]. Microscopy and some rapid diagnostic tests
(RDTs) meet this threshold [6]. In the absence of fever, some individuals will have parasitae-
mia levels detectable by microscopy and RDTs. These asymptomatic infections are particularly
common in areas of high transmission (i.e., above 25 clinical cases per week per 1,000 persons)
[7], where high levels of human immunity allow older individuals to carry relatively large para-
site burdens chronically [8]. Such individuals would be detected within mass screen and treat
(MSAT) programmes using currently available diagnostics. However, through the use of
molecular amplification methods, it is now clear that many individuals harbour low-density
malaria infections beneath the limit of detection of both microscopy and RDTs [9]. Meta-anal-
yses indicate that molecular methods detect up to twice as many P. falciparum infections as
RDT or microscopy [10], and approximately 5 times as many P. vivax infections [11,12]. This
gap in sensitivity may be more pronounced when compared against ultra-sensitive molecular
Box 1. Terminology
Malaria typologies
Malaria typology is the characterisation of malaria epidemiology according to ecology
(climate and environment) and other determinants of transmission for the purpose of
guiding malaria interventions. Relevant ecologies include (but are not limited to) savan-
nah, lowland plains and valleys, highlands, desert and oasis, forest and jungle, coastal
and marshland, and urban or peri-urban. The unique features of malaria transmission
in each ecological area are also strongly driven by region-specific vectors and parasites
(species, biology, behaviour, insecticide and antimalarial drug susceptibility), human
biology and behaviour, and economic and health-system factors. These are discussed
more comprehensively in [4] and [5].
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Fig 1. Research needs and programmatic applications in measuring malaria transmission across the transmission spectrum. Range
of malaria transmission intensity (grey line) from very high intensity to postelimination settings. Current metrics (navy blue line) used for
routine measurement of malaria transmission at each level of transmission intensity. Knowledge gaps (orange line) in understanding the biology
and epidemiology of malaria transmission and the infectious reservoir at all levels of transmission intensity. Technical gaps (light blue line) in the
accurate measurement of transmission at each level of transmission intensity. Programmatic actions (yellow line) required for the interruption
of transmission and the prevention of reintroduction at each level of transmission intensity.
https://doi.org/10.1371/journal.pmed.1002452.g001
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methods [13]. Lack of sensitivity of diagnostic detection is more acute for P. vivax infections,
which circulate at lower parasite densities hampering accurate estimates of true prevalence.
There are also other unique challenges presented by P. vivax that make characterising its trans-
mission reservoir problematic (Box 2) [14–18].
Diagnosis and treatment of clinical malaria is vital for disease control, particularly if this
can be rapidly implemented to reduce the likelihood of gametocyte production. There is also a
good public health rationale for identifying and treating ‘asymptomatic’ malaria detectable
with microscopy or RDTs, as it is increasingly recognised that this is associated with ongoing
morbidity (e.g., anaemia, increased susceptibility to bacterial infections, and cognitive func-
tion; reviewed in [8]). If the aim is malaria elimination, the contribution of low-density infec-
tions to transmission needs to be considered given that, where data are available, low-density
infections represent a significant proportion of malaria infections and can be the majority in
low-endemic areas [9,10,19,20].
While the countries that have achieved malaria elimination to date have done so largely
without specific attempts to detect and treat low-density parasitaemia, these may not be repre-
sentative of malaria typologies in higher-transmission settings. In many areas, the persistence
of malaria can occur despite high coverage of vector control measures and the availability of
effective treatment, suggesting that novel approaches are needed for both surveillance and
interventions that will accelerate the elimination process [19,21]. Furthermore, studies have
documented the failure of strategies to reduce clinical malaria incidence and transmission,
such as MSAT, when the transmission reservoir is not adequately identified and targeted with
the currently available field diagnostics [22].
It follows that the cost-effectiveness of existing or novel surveillance methods and interven-
tions in reducing malaria transmission cannot be predicted or evaluated unless the relative
contribution to transmission of (1) clinical/symptomatic malaria, (2) asymptomatic
Table 1. Summary of currently available entomological malaria transmission metrics.
Metric Definition [3] Measure of
transmission
Sampling method and resolution Discriminatory power
Entomological
inoculation rate
(EIR)
Number of infective bites received
per person in a given unit of time,
in a human population
Transmission
intensity
• Human landing collection; light
traps
• Resolution: Household or
community level
• Insensitive at low transmission
• Lack of standardised sampling design
• Collected by malaria control
programmes
Sporozoite rate
(SR)
Percentage of female Anopheles
mosquitoes with sporozoites in the
salivary glands
Risk of infection • Human landing catch; baited
traps; gravid traps
• Resolution: Community level
• Insensitive at low transmission
Human biting rate
(HBR)
Average number of mosquito bites
received by a host in a unit of time,
specified according to host and
mosquito species
Risk of exposure • Human landing collection
• Resolution: Person or
community level
• Allows determination of the primary
vector
Vectorial capacity Rate at which given vector
population generates new
infections caused by a currently
infectious human case
Efficiency of
transmission
• Derived from human biting rate,
parasite inoculation period,
mosquito to human density and
mosquito survival
• Resolution: Community level
• Measures potential, not actual, rate of
transmission—includes no
parasitological information
• Sensitive to changes in mosquito
survival and biting behaviour but may
not translate to significant change in
human incidence
• Can be useful when infection rates
are low and mosquito sampling
difficult
https://doi.org/10.1371/journal.pmed.1002452.t001
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parasitaemia (detectable by microscopy or RDT), and (3) low-density parasitaemia (not detect-
able by microscopy or RDT) are estimated for a particular setting. With an increasingly diverse
array of potential approaches for malaria elimination [18], but with limited human and finan-
cial resources [23], characterising the contribution of low-density parasitaemia to transmission
will help to focus elimination efforts.
Low-density parasitaemia and transmission
There are currently no field diagnostics with sufficient sensitivity to identify low-density sub-
microscopic parasitaemia, though various approaches are under evaluation for performance
and scalability (discussed in the malERA Refresh ‘Tools’ paper) [18]. However, even if all
infected individuals could be identified, there is a need to understand who is infectious to mos-
quitoes and for how long.
Understanding the contribution of low-density parasitaemia to the infectious reservoir for
a given malaria typology is critical to determine the diagnostic sensitivity required. It will also
affect how much effort a programme should commit to detecting and treating these infections
and when and where this effort is best deployed. As noted above, the proportion of low-density
parasitaemia increases as transmission declines [9,10,19,20,24]. Recent findings from Senegal
also suggest that the efficiency of human-to-mosquito transmission increases with decreasing
transmission intensity [25].
Table 2. Summary of currently available malaria transmission metrics in humans.
Metric Definition [3] Measure of transmission Method Discriminatory power
Annual blood
examination rate
(ABER)
The number of people receiving a
parasitological test for malaria per unit
population per year
Level of diagnostic monitoring
activity
Microscopy or
RDT
• Dependent on health-system
provision
Case, confirmed Malaria case (or infection) in which the
parasite has been detected in a
diagnostic test
Current transmission or
incidence if data collection is
repeated or routine
Microscopy or
RDT positive
• Insensitive at low transmission;
saturates at high transmission
• Underestimates due to system
inadequacies and poor health-
seeking behaviour
Case, fever The occurrence of fever (current or
recent) in a person
Current transmission or
incidence if data collection is
repeated or routine
Reported or
observed fever
• Overestimates malaria infection
Proportion of fevers
parasitaemic (PFPf)
*
Proportion of fever cases found to be
positive for Plasmodium
Current transmission or
incidence if data collection is
repeated or routine
Microscopy;
RDT; NAAT
• Depends on diagnostic sensitivity
• Insensitive at low transmission
Slide positivity rate
(SPR)
Proportion of blood smears found to be
positive for Plasmodium among all blood
smears examined
Current transmission or
incidence if data collection is
repeated or routine
Microscopy • Depends on ABER
• Insensitive at low transmission
RDT positivity rate
(RDT-PR)
Proportion of positive results among all
RDTs performed
Current transmission or
incidence if data collection is
repeated or routine
RDT • Depends on RDT sensitivity
• Insensitive at low transmission
Parasite rate (PR) Proportion of the population found to
carry asexual blood-stage parasites
Current transmission or
incidence if data collection is
repeated or routine
Microscopy;
RDT; NAAT
• Depends on diagnostic sensitivity
• Insensitive at low transmission
Gametocyte rate
(GR)
Percentage of individuals in a defined
population in whom sexual forms of
malaria parasites have been detected
Potentially infectious human
population
Microscopy;
NAAT
• Depends on diagnostic sensitivity
• Insensitive at low transmission
*No WHO definition is available for this term.
Abbreviations: ABER, annual blood examination rate; GR, gametocyte rate; NAAT, nucleic acid amplification test; PFPf, proportion of fevers parasitaemic;
PR, parasite rate; RDT, rapid diagnostic test; RDT-PR, RDT positivity rate; SPR, slide positivity rate.
https://doi.org/10.1371/journal.pmed.1002452.t002
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Box 2. P. vivax and P. ovale
P. vivax and P. ovale have a dormant liver stage, the hypnozoite, which is undetectable
by currently available diagnostic methods. Periodic reactivation of hypnozoites results in
repeated blood-stage infection (relapses) occurring weeks, or even years, following the
initial infection. As control efforts reduce the incidence of P. falciparum cases, P. vivax
cases can remain relatively stable and become a greater proportion of malaria cases over-
all [16]. P. vivax is refractory to traditional vector control methods: hypnozoites enable
the parasite to evade conditions unfavourable to transmission and will survive in the
host following schizonticidal anti-malarial therapy. Without new anti-hypnozoite drugs
or vaccines that could be used safely across entire populations, the P. vivax/ovale trans-
mission reservoir cannot be targeted, making elimination of these parasites challenging
in any setting.
Key advances
Relapses drive transmission
• In children in Papua New Guinea, 4 of every 5 P. vivax infections and 3 of every 5 P.
ovale infections were caused by relapses [14].
• Both primary and relapse P. vivax infections generate gametocytes, which typically
appear before clinical symptoms, and promote onward ‘silent’ transmission of the par-
asite [15].
• Estimating transmission using the typical entomological measures is of limited rele-
vance when clinical disease can emerge from an individual not recently infected by a
mosquito bite.
Research needs
Detection of hypnozoites to inform targeted drug or vaccination strategies
• Access to existing anti-hypnozoite therapy needs to be expanded where possible in
order to reduce the burden of disease and minimise the risk of human-to-mosquito
transmission via relapse.
• However, several barriers to mass drug administration (MDA) for P. vivax exist. The
8-aminoquinolines primaquine and tafenoquine are the only known anti-hypnozoite
drugs. Both drugs are contraindicated in pregnancy and individuals with glucose-
6-phosphate dehydrogenase deficiency [17,18]. Even if rapid, accurate point-of-care
tests were available to exclude these individuals from treatment, a significant propor-
tion of the population (typically >10%) will remain untreated.
• Without being able to identify hypnozoites, MSAT is of no practical value in reducing
P. vivax or P. ovale transmission [14].
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Currently, the only way to measure human infectiousness is by feeding colony-reared mos-
quitoes either on humans directly (direct feeding assay [DFA] [26,27]) or on infected human
blood via a membrane (direct membrane feeding assay [DMFA] [28]). A number of studies
have used these methods to estimate the contribution of low-density infections to malaria
transmission [29–34]. For example, studies in Burkina Faso using DMFA found that 28.7% (25
out of 87) of infectious individuals were microscopy negative, causing 17.0% of mosquito
infections [29]. Similarly, in Thailand, DFA studies found that 21% (13 out of 62) individuals
submicroscopic for either P. falciparum or P. vivax were able to infect mosquitoes [34]. These
preliminary studies suggest that surveillance systems could be modified in the future to detect
submicroscopic infections and direct transmission reduction efforts. However, understanding
the relationship between infectivity as measured in feeding assays and the infectivity in natural
transmission settings to local mosquitoes is still a major research challenge. Furthermore, few
empirical studies have quantified the proportion of the overall population that is both submi-
croscopic and infectious, particularly in low-transmission settings (i.e., less than 8 clinical
cases per week per 1,000 persons) [7]. This is needed to determine when and where treating
low-density parasitaemia is critical for interrupting transmission and the diagnostic sensitivity
required to target them. Mathematical models suggest that conventional diagnostics can detect
55% of the infectious reservoir, but with a 100-fold increase in sensitivity of detection level,
i.e., from 200 to 2 parasites/μL of blood, up to 95% of infectious individuals could be identified
[35]. This level of diagnostic sensitivity could transform our understanding of the malaria
transmission reservoir, allowing the development and delivery of better strategies to disrupt
transmission toward malaria elimination.
Detecting gametocytes
All malaria infections have the capacity to produce gametocytes. Therefore, in the context of
community chemotherapy programmes, treating any individuals who test positive for asexual
parasites is a realistic programme aim. However, research tools that measure gametocytaemia
are essential to further our understanding of transmission biology and to define the popula-
tions and individuals that drive transmission. Some studies have suggested that transmission
efficiency may increase as malaria prevalence falls due to higher gametocyte densities. As the
development of new transmission-blocking drugs and vaccines advances, understanding the
factors that drive this transmission efficiency will be needed to determine in which settings
interventions can be successfully trialled and/or implemented [25]. Although gametocytes can
• Compared to P. falciparum, P. vivax and P. ovale present as much lower parasite densi-
ties; therefore, determining the appropriate limit of detection for new diagnostics will
be a major challenge.
Improve understanding of parasite-vector bionomics
Parasites can be transported undetected into areas where malaria has been eliminated,
leading to outbreaks and the reestablishment of transmission where conditions are
receptive. More effort needs to be directed at understanding specific parasite vector
interactions to develop targeted vector control strategies for P. vivax/ovale to reduce the
risk of mosquito-to-human transmission.
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be identified using microscopy, they often exist at low densities and may circulate only tran-
siently in the blood. RDTs do not differentiate between gametocytes and asexual parasites. The
limit of detection of microscopy is 8–16 gametocytes/μL of blood [30,31]. Predictably, molecu-
lar methods are more sensitive, with 0.3 mature females/μL of blood detected with Pfs25
reverse transcription qPCR (RT-qPCR) and 1.8 mature males/μL of blood with Pfs230p RT-
qPCR [36]. As gametocyte densities are low, the increased sensitivity of molecular methods
considerably increases gametocyte detection rates. For example, a recent study in Kenya found
that Pfs25 RT-qPCR detected gametocytes in 44% of the population compared with only 2.6%
detected by microscopy [37].
While there is an overall positive association between mosquito infection rates and gameto-
cyte density, there is also evidence of infectiousness for individuals with very low gametocyte
densities [27,38]. As the majority of malaria infections are submicroscopic, even if only a small
proportion of these individuals are infectious, the contribution to the transmission reservoir is
potentially significant enough to impact elimination programmes.
Where data are available, they suggest differences between high- and low-transmission set-
tings in the gametocyte density needed for human infectivity to mosquitoes. In African popu-
lations, submicroscopic P. falciparum gametocytaemia is common, and studies in Kenya have
found that the majority of infectious children (43 out of 62) had submicroscopic gametocytae-
mia [30,31]. In contrast, in Cambodia, falciparum-infected subjects with detectable gameto-
cytes by microscopy were significantly more likely than gametocyte-negative individuals to
infect mosquitoes, and those with microscopy-detectable gametocytaemia were the source of
the majority of all mosquito infections [39].
Heterogeneity in the transmission reservoir
While data demonstrate an advance in our understanding of malaria transmission, they are
limited and suggest the infectious reservoir differs across malaria typologies [24]. Most studies
investigating human infectiousness have been conducted in high-transmission settings. There
is a particular need for data from low-transmission and near-elimination settings, where tem-
poral, spatial, and demographic heterogeneity in transmission can often be more pronounced.
Longitudinal data characterising the transmission reservoir are also needed. These would not
only allow more accurate assessments of the contributions of the different density infections
but could also inform the sequence of intervention delivery needed to reduce transmission.
Similarly, these data would inform the necessary intervention changes to most effectively tran-
sition countries from high to low transmission and ultimately elimination [40]. A key consid-
eration is to advise when malaria control measures should be reoriented following elimination
without the risk of reintroduction, particularly in the context of declining human immunity to
malaria and the potential for outbreaks.
As transmission declines and heterogeneity increases, programmes need to adjust in order
to respond to increasingly rare clinical cases. The persistence of residual transmission requires
more aggressive and/or novel strategies, and targeting these areas will be key to local elimina-
tion. Significant progress has been made in approaches to identify transmission foci using a
number of field-based, geo-spatial, and modelling approaches [41–53]. However, even where
hotspots of malaria transmission can be identified, attempts to target these foci may fail against
a background of low-level but widespread transmission [54]. Local implementation and high-
coverage control interventions linked to surveillance information will be needed to adequately
clear the reservoir at all levels of transmission.
Surveillance systems at low-transmission settings will also need to be equipped to monitor
emerging insecticide and drug resistance [55,56] that may threaten the success of existing
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interventions [56]. Longitudinal monitoring of resistance markers via sentinel surveillance
sites could prove invaluable for tracking risk of rebound or reintroduction. However, there are
currently no field-based diagnostic tests for drug resistance, and more detailed information
may be needed on local drug-resistance patterns in asymptomatic/low-density infections, par-
ticularly related to any changed infectiousness to mosquitoes.
Research agenda for measuring transmission
Improved and validated metrics of transmission would enable the optimal design of control
programmes and surveillance systems needed for malaria elimination [23]. This would include
the ability to better track progress, confirm cases and foci, and identify and contain reintro-
duction of transmission, should it occur. Validated transmission metrics are also the key out-
come to be measured in field trials evaluating the effectiveness of transmission-blocking
interventions [18] and can be used to improve mathematical models assessing potential inter-
vention combinations [7].
Measures of malaria transmission can be defined at different points in the transmission
cycle (Fig 2). Since 2011, progress has been made in understanding the advantages and limita-
tions of transmission metrics across epidemiological settings [57,58]. Further work is needed
to better quantify the correlations between metrics, standardise their application for use in
programmatic surveillance activities, and develop and validate new metrics. However, it is nec-
essary that transmission metrics are reliable and reproducible on a consistent basis and can be
assembled through existing national systems.
Entomological metrics
Between 30–40 species of Anopheles have been identified as vectors of human malaria, exhibit-
ing varying feeding behaviours and preferences, habitats, and ecologies. Within this complex-
ity, there is a need to standardise current metrics and develop more efficient sampling
techniques [57] (Table 1). Whilst developments in sampling methods have been made to eval-
uate biting densities and infection rates [59–63], human landing collection (HLC) sampling
remains the gold standard for providing epidemiologically relevant mosquito-to-human trans-
mission metrics, despite inherent risks [64,65]. Alternative technologies to HLC are being
tested that limit human exposure [66,67] and include traps with attractants that mimic a
human host [68,69].
New approaches are particularly needed in settings where vector densities are low or het-
erogeneous. For example, reexamination of vectorial capacity using mathematical modelling
to simulate settings with different baseline epidemiological and entomological characteristics
has led to new insights into the effective deployment of vector control measures [70]. Techno-
logical advances in geolocation and mapping can precisely identify vector habitats that coin-
cide with human activity and movement [71]. This information can be used to determine
potential exposure points, enabling targeted sampling in these foci of transmission risk. Other
innovative technologies include high-throughput technology, such as infrared spectrometry,
to evaluate large samples of mosquitoes for vector age, species, and infection status [72–74],
thus providing a measure of vector density and indicating the risk of malaria reintroduction.
In this regard, as with parasite drug resistance, longitudinal monitoring of insecticide resis-
tance via sentinel surveillance could prove invaluable.
Human metrics
Current epidemiological metrics of malaria transmission in humans, diagnosed via passive
and active systems, microscopy and RDTs, remain key for national malaria control
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programmes in tracking progress in the reduction of malaria cases and identifying outbreaks
and epidemics (Table 2). These data are complemented with large-scale surveys, such as the
Demographic and Health Surveys (DHS), the Malaria Indicator Surveys (MIS) and UNICEF
Multiple Indicator Cluster Surveys (MICS). However, as transmission declines to low
Fig 2. Key programmatic and research metrics across the malaria parasite transmission cycle. NAAT, nucleic acid amplification
test; RDT, rapid diagnostic test.
https://doi.org/10.1371/journal.pmed.1002452.g002
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intensity, clinical cases become rare, slide and RDT positivity rates low, and transmission pat-
terns increasingly heterogeneous.
To generate practical estimates of infection without excessive sampling, more sensitive
diagnostics and/or combinations of diagnostic approaches are needed. While the utility of
RDTs will need to be monitored in regions where deletions in the gene encoding HRP2 have
been detected in the parasite population [75,76], research is currently underway to develop
RDTs with detection thresholds corresponding to 10–20 parasites/μL or lower [77]. The
development of highly sensitive nucleic acid–based tests for parasite detection [78,79], and
hemozoin detection using nuclear magnetic resonance [80,81], is also ongoing and may be
promising. While tests using molecular methods would increase the number of infections
identified, their widespread deployment in low-transmission settings is probably not currently
cost-effective for the identification of incident infections. Additionally, in recognition of het-
erogeneity, approaches should shift from tracking national or regional progress in malaria
control towards targeted sampling and community-based surveys characterising transmission
risk in key population groups. Once elimination has been achieved, maintaining ‘zero’ trans-
mission will depend on the health system’s ability to identify any emergent malaria cases,
triggering case-based investigation to determine the origin (local or imported) and prevent
onward transmission.
Metrics to understand transmission
Recent technical advances have produced a number of transmission metrics that are suitable
for low-transmission settings (Table 3). Molecular force of infection (mFOI) and multiplicity
of infection (MOI) both use parasite genotyping methods to assess the complexity of parasite
infections [82]. mFOI can identify superinfected individuals that carry parasites from more
than 1 infection, providing a more detailed measure of transmission compared to force of
infection based on less sensitive methods (Table 2). Sequencing to determine parasite popula-
tion structure can also be used to characterise transmission by measuring the genetic related-
ness between infections in space and time. Other measures, such as allelic richness, can
indicate the level of genetic diversity, which is expected to decline as transmission declines
[83,84]. Even more refined sequencing approaches might be capable of assigning parasites as
imported or local for monitoring the origin of infections.
Antibody seroprevalence and the seroconversion rate (SCR) exploit human antibody
responses to characterise previous parasite exposure and are specific to a particular antigen
or combination of antigens [85]. Studies using enzyme-linked immunosorbant assays (ELI-
SAs) have shown serological measures correlate well with parasitological and entomological
measures in describing transmission levels and spatial and demographic risk [86,87].
Uniquely, serology, when combined with age, allows retrospective examination of exposure
history, including the effects of interventions and the absence of recent exposure in elimina-
tion settings. High-throughput platforms, such as microarray and bead-based multiplex
assays, allow screening of large numbers of potential antigenic targets with specific charac-
teristics [87,88–91]. Targets of interest include stage- or species-specific biomarkers, partic-
ularly for P. vivax [88], serological signatures of hypnozoite carriage [92], and vector-
specific antigenic targets in mosquito saliva [93,94]. The programmatic applications of
serology have yet to be fully tested, though various approaches are being evaluated, includ-
ing serological markers of incident infections [89,95–109]. Research is currently underway
to identify a variety of biomarkers indicative of recent infection that are detectable for dif-
ferent durations following parasite infection, allowing finer-scale estimation of time since
infection.
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Table 3. Advances in the development of metrics for measuring malaria transmission.
Metric Definition Measure of transmission Method Discriminatory power
Force of infection Rate at which susceptible
individuals contract malaria
• Probability of transmission Time from birth to first malaria
episode; microscopic detection of
parasites following successful
antimalarial treatment
• Difficult to measure
• Difficult to standardise
• Depends on diagnostic
sensitivity
• Cannot differentiate
superinfections
mFOI The number of new parasite
clones acquired by a host over
time
• Population-level
transmission intensity
• Transmission heterogeneity
Cohort study >6 months with
parasite genotyping
• Highly sensitive for
monitoring changes in
malaria exposure
• Superinfections can be
differentiated
MOI The number of different
parasite strains coinfecting a
single host
• Population-level
transmission intensity
• Transmission heterogeneity
Parasite genotyping of positive
samples
• Saturates at high
transmission
• Restricted by age
dependency
• Insensitive at low
transmission
• Highly sensitive to spatial
heterogeneity
• Highly sensitive to increases
in imported infection
• Less sensitive to changes in
seasonality
Genotyping:
SNPs or amplicon
sequencing
• Genetic diversity, i.e.,
number of alleles in a
population
• Parasite signatures to map
geographical relatedness of
infection (i.e., spatial–
temporal transmission)
• Population-level
transmission intensity
• Transmission heterogeneity
• Geographical tracking of
transmission patterns
• Haplotypes composed of >12
informative SNPs from single
clone infections
• Haplotypic signatures from
highly variable loci
• Sensitive to changes in
malaria exposure and
spatial–temporal flow of
infection
• Standardisation of measures
needed
• Methods for analysis and
interpretation of data needed
Antibody
seroprevalence
The percentage of seropositive
individuals in a population
• Population-level
transmission intensity
Seronegative or seropositive
defined using appropriate cutoff
points
• Dependent on antibody
target tested
• Saturates at high
transmission
• Sensitive at low
transmission
SCR The rate (typically annual) by
which seronegative individuals
become seropositive upon
malaria exposure
• Population-level
transmission intensity
• Temporal changes in
transmission can be
detected from a single
sampling time point
Detection of antibodies in sera
using serological assay (IFAT,
ELISA, bead-based assays
microarray)
• Dependent on antibody
target tested
• Restricted by age
dependency
• Saturates at high
transmission
• Sensitive at low
transmission
• Sensitive to risk of malaria in
absence of transmission
Abbreviations: ELISA, enzyme-linked immunosorbant assay; IFAT, Immunofluorescence Antibody Test; mFOI, molecular force of infection; MOI,
multiplicity of infection; SCR, seroconversion rate.
https://doi.org/10.1371/journal.pmed.1002452.t003
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For all these metrics, however, standardisation of methods is necessary, as well as a quanti-
tative comparison to understand the relationship with existing and other new metrics. The
development of operationally suitable platforms will ultimately be required to inform real-
time or rapid response in programmatic settings. In relation to this, there needs to be a clearer
understanding of what measures are needed to better define and monitor transmission, and
what measures are useful for control programmes. New approaches to analyse metrics from
different sources to improve estimates of transmission, or confirm its interruption, are needed.
Looking to the veterinary world could be informative, where probability-based survey meth-
ods such as “freedom from infection” are used for animal disease surveillance in the food and
agriculture industry [110]. These methods are based on defining the probability that a popula-
tion is free of infection, allowing operational surveillance thresholds to be set based on the cho-
sen sampling frame and the sensitivity of available diagnostics. Adapting these strategies for
use in malaria surveillance will require tailoring the methods for specific malaria transmission
measures.
Multimetrics to characterise transmission in time and space
The increasing availability of spatial databases on parasite rate [111,112], serology, vectors
[113], malaria genetic epidemiology [114], and human population movements [115–118],
together with the increased flexibility and computational efficiency of mathematical and statis-
tical modelling methods [119,120], have led to substantial advances in the spatial–temporal
characterisation of malaria transmission intensity. To date, most of these methods have
focused on a single metric of endemicity or have relied on parameters derived from small stud-
ies. However, dynamic models are being developed that will capture the effect of human popu-
lation movements, and could incorporate multimetric ensembles to allow self-consistent
mapping across the entire spectrum of transmission settings [7]. For these technologies to
achieve the greatest impact, they will need to be linked to and used by control programmes to
inform operational decision-making in real time.
Summary
Considerable progress has been made not only in understanding the biology and epidemiology
of malaria transmission but also in the development of new tools to more accurately quantify
transmission; however, challenges remain and Box 3 summarises this Panel’s research and
development agenda. The foremost of these is an incomplete understanding of the infectious
reservoir in low-transmission and elimination settings, particularly the relative infectiousness
of (1) asymptomatic individuals and (2) susceptible vector species across a variety of malaria
typologies. The spatial and temporal heterogeneity at which these factors interact will change
as countries transition to lower transmission intensity.
The absolute and relative incidence of clinical and asymptomatic infections can vary widely
between different low-transmission settings. Transmission can occur as focal outbreaks caused
by human and vector migration. It can also persist for long periods despite aggressive control
strategies or quickly rebound after reaching zero. These scenarios are caused by varying pat-
terns of malaria risk across demographic groups, vectors, and parasite species in different
ecological settings, which may not be easily captured by simple incidence and prevalence
measures.
The application of new and/or refined metrics for routine surveillance activities or research-
specific contexts requires investigation. This needs to be done in the context of existing stan-
dard measures and the newer data collection platforms to understand the true utility. Metrics
will also need to be optimised for the quality of the healthcare system in which they will be
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Box 3. Research and development agenda
Characterising the reservoir
Objective: Determine the relative contribution to transmission of symptomatic malaria,
asymptomatic malaria detectable with microscopy or RDTs, and low-density infections
detectable by molecular methods across different malaria typologies; data from low-
transmission settings are particularly required.
Research goals
• Determine the kinetics of infectiousness of low-density parasitaemia.
• Determine the infectiousness of low-density gametocytaemia.
• Refine mosquito feeding assays (DMFA or DFA) of human infectivity to mosquitoes
and validate these against natural infectivity to local vector species.
• Determine the required sensitivity of field-based diagnostics to identify malaria infec-
tions contributing to transmission.
• Continue to develop field-based molecular and serological diagnostics with sensitivi-
ties relevant for evaluation of infectious low-density parasitaemia and
gametocytaemia.
• Investigate non-invasive diagnostics of malaria infection and infectivity.
• Develop hypnozoite diagnostics predictive of P. vivax/P. ovale relapse and subse-
quent infectivity.
• Develop cost-effective programmatic triggers and protocols for the optimal deploy-
ment of transmission-based diagnostic tests and their incorporation within surveil-
lance systems.
• Evaluate the cost-effectiveness of programmatic actions and interventions directed
by transmission-based diagnostics.
• Characterise changes in the transmission reservoir as transmission declines.
• Conduct longitudinal studies in areas of declining transmission to investigate
changes in the nature and distribution of the transmission reservoir.
• Evaluate which surveillance activities and metrics are most informative and cost-
effective for programmatic goals.
• Develop operational methods to rapidly identify antimalarial drug-resistant parasites
and insecticide-resistant vectors.
• Determine the relevance of spatial–temporal heterogeneity in the transmission reser-
voir to the acceleration of elimination.
• Identify foci of residual transmission.
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implemented. The same applies to the infectious reservoir. Whilst its characterisation across
different transmission settings is important, translating this information into actionable pro-
grammatic decisions will be key to achieving zero malaria transmission.
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